T he development of an effective vaccine against HIV infection and AIDS is a global public health priority. Accordingly, there has been much scientific focus on SIV infection of nonhuman primates, especially rhesus macaques, which provides a useful model to inform HIV pathogenesis and study the efficacy of vaccine candidates (1, 2) . In the past decade, most work on SIV-specific CD8 + T cell responses in the rhesus macaque model has centered on the MHC class I (MHC I) molecule Mamu-A*01 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . More recently, however, the scope of immunological studies in this model has expanded to include additional MHC I molecules that display distinct biological properties. Mamu-B*17, which is present in .12% of captive Indian rhesus macaques (21) , is associated with the control of SIV replication in vivo (22) (23) (24) (25) (26) , although it should be noted that inheritance of this allele alone does not predict a favorable outcome and that the immunological basis for this association remains unclear. In humans, it is well-established that HLA-B*27 and HLA-B*57, the gene products of which present HIV-derived epitopes that elicit highly effective CD8 + T cell responses (27) (28) (29) (30) (31) , are associated with reduced virus loads and delayed disease progression in HIV-infected individuals (27, (32) (33) (34) (35) . By analogy, the study of Mamu-B*17-positive rhesus macaques provides an opportunity to understand how specific MHC I molecules might impact AIDS virus replication in a controlled setting (31) .
The peptide-binding specificity of Mamu-B*17 has been identified, together with a range of presented SIV-derived epitopes that exhibit diverse lengths and antigenicities (36) . Strikingly, no immunodominant Gag-derived epitopes have been described (36) . In contrast, many targeted epitopes emanate from the smaller regulatory/accessory proteins Nef and Vif (Table I) (37) . Given the critical roles of these proteins with respect to infectivity and pathogenicity, such epitopes may be appealing targets for vaccine development. CD8 + T cell responses restricted by Mamu-B*17 can be detected during both the acute and chronic phases of SIV infection (36) , which suggests that this MHC I molecule could play important roles in the control of viral replication throughout the course of infection. However, the efficacy of immunodominant CD8 + T cell responses can be impaired by the selection of viral escape variants (38) . Indeed, the emergence of escape mutations frequently correlates directly with the loss of viral suppression (38) (39) (40) . Nevertheless, this phenomenon can impact viral fitness and reflects the potency of certain CD8 + T cell response (41) . Many escape mutations within viral epitopes involve anchor residue substitutions that impede peptide binding to the corresponding MHC I molecule. In contrast, much of the observed sequence variation within Mamu-B*17-restricted epitopes does not seem to impair peptide-MHC I (pMHC I) binding substantially (42) . Moreover, in the Mamu-B*17 setting, the C-terminal tryptophan anchor residues remain conserved, and amino acid substitutions only rarely affect the N-terminal anchors at positions 1, 2, or 3. Although variants of the HW8 epitope (Vif [66] [67] [68] [69] [70] [71] [72] [73] ) can display substitutions in the N-terminal anchor residue, they maintain the ability to bind Mamu-B*17, which likely reflects amino acid compatibility and pocket B flexibility. Similarly, the Ile-to-Thr replacement at the N-terminal amino acid residue of the IW9 epitope (Nef 165-173 ) does not impact either Mamu-B*17 binding or CD8 + T cell recognition; rather, this mutation hinders Ag processing and/or presentation (42) . Collectively, these features indicate that Mamu-B*17-restricted epitopes are favorable targets for effective CD8 + T cell immunity. Indeed, Mamu-B*17 + elite controllers (ECs) have been shown to resist rechallenge with variant SIV strains containing multiple escape mutations, and CD8 + T cell clones derived from ECs were more effective at suppressing viral replication than those derived from progressors (43) .
The characteristics of peptide presentation by MHC I play a pivotal role in the antigenicity of an epitope (44) (45) (46) (47) (48) (49) . Accordingly, we determined the structures of eight SIV mac 239-derived epitopes in complex with Mamu-B*17 to define the atomic basis for effective epitope presentation by this protective MHC I molecule. Structural analysis revealed a novel peptide-binding strategy for the accommodation of diverse antigenic peptides, which informs our understanding of the association between Mamu-B*17 and the control of SIV replication.
Materials and Methods

Peptide synthesis
The peptides used in this study (Table I) were synthesized at ∼90% purity as determined by HPLC reverse-phase chromatography (Scilight-Peptide). Peptides were stored in lyophilized aliquots at 280˚C and dissolved in DMSO before use.
Protein expression, refolding, and purification Mamu-B*17 H chain (extracellular domain, aa residues 1-276), human b 2 -microglobulin (hb2m), and rhesus macaque b 2 -microglobulin (rb2m) were expressed as inclusion bodies in Escherichia coli strain BL21 (DE3) and refolded with synthetically prepared SIV mac 239-derived peptides. Refolding was performed as described previously (50) . Briefly, Mamu-B*17 H chain, b 2 -microglobulin (b2m), and peptide were mixed at a molar ratio of 1:1:3 in refolding buffer (1 L comprising 100 mM Tris-HCl [pH 8], 400 mM L-Arg, 2 mM EDTA, 5 mM GSH, and 0.5 mM GSSG). After 24 h incubation at 4˚C, the soluble portion of the refolded complex was concentrated and purified by gel filtration, followed by anion exchange chromatography and a second round of gel filtration, then finally concentrated to 10 mg/ml in 20 mM Tris-HCl (pH 8) and 50 mM NaCl for crystallization. The Mamu B*17 Vif 66-73 HW8 (HLEVQGYW) protein was refolded with hb2m; all other complexes were refolded with rb2m.
Protein crystallization and data collection
Protein concentrations were determined using a BCA protein assay according to the manufacturer's instructions (Pierce). Crystal screens were initiated using commercial kits (Hampton Research). All crystallizations were performed using the hanging drop vapor diffusion technique. Plates were incubated at 291 K and examined after 72 7.5] , and 25% w/v polyethylene glycol 3350). All crystals were soaked in reservoir solution supplemented with 20% glycerol as a cryoprotectant, then flash-cooled and maintained at 100 K in a cryostream. Data collection was performed in-house on a Rigaku R-AXIS IV++ image plate with a Rigaku MicroMax007 rotating-anode x-ray generator (Rigaku) operated at 40 kV and 20 mA (Cu Ka; l = 1.5418 Å ). Data were processed and scaled using HKL2000 (51) .
Structure determination, refinement, and analysis
The Mamu-B*17-HW8 structure was solved by the molecular replacement method using the HLA-B*5703 molecule (Protein Data Bank code 2BVO) as the search model with the program package Mosflm (52) and scaled with the program SCALA of the CCP4 program suite (53) . The other datasets were determined by molecular replacement using the solved Mamu-B*17-HW8 structure as the search model with MOLREP (54) . Extensive model building was performed by hand with COOT (55) , and restrained refinement was performed using REFMAC5. Additional rounds of refinement were performed using the PHENIX package (56) . The final structures displayed good stereochemistry (Table II) , as assessed by the program PROCHECK (57), comprising residues 1-276 of the H chain and residues 1-99 of b2m. Structural figures were prepared with PyMOL. Solvent accessible surface areas were calculated with AreaMol in CCP4. 
Protein structure accession numbers
Results
The overall structures of Mamu-B*17 with eight different SIV mac 239-derived peptides
The structures of Mamu-B*17 complexed with eight different immunogenic SIV-derived peptides were determined in this study (Table I ). X-ray data collection statistics are summarized in Table   Table I (12328) 32167 (7659) 32635 (3169) 28767 (2814) 20992 (2000) 13578 (1391) 27152 (2628) 36987 (3597) No. of unique reflections 22575 (3244) 7659 (1823) 8588 (834) 8460 (827) 2915. (303) 2424 (253) 4937 (469) 9733 (972) No. of molecules in the asymmetric unit No. of residues in outlier region (%)
Values in parentheses refer to the highest resolution shell of data. Rfree is calculated as for Rcryst but using 5% of reflections sequestered before refinement.
II. As expected, the overall domain arrangements and topologies of these Mamu-B*17 structures are similar to those of other mammalian MHC I molecules. The extracellular region of the Mamu-B*17 H chain forms a bedlike shape containing three domains (a1, a2, and a3). Specifically, the bedrail is composed of antiparallel a1 and a2 helices, which are supported by an eightstranded b-sheet bedplate. The bound antigenic peptide lies along the bedrail. The a3 domain and b2m occupy the standard positions below the bedplate (Fig. 1) . Both Mamu-B*17 and HLA-B*57 are enriched in EC cohorts and associated with the control of SIV and HIV replication, respectively. Amino acid sequence alignments ( Fig. 2) reveal that Mamu-B*17 is quite similar to HLA-B*57, displaying 85.14% identity with HLA-B*5703. Moreover, the overall three-dimensional structure of Mamu-B*17 is similar to that of HLA-B*5703, with a root mean square difference of 0.709 Å .
Various conformations of the bound peptides
Superposition of all eight peptides revealed the structural basis for length heterogeneity within Mamu-B*17-restricted epitopes (Fig.  3A) . The majority of bound peptides adopt similar conformations with the P2 and C-terminal (Pc) residues serving as anchors, consistent with other pMHC I structures (Fig. 3A) . Exceptions to this rule are HW8 and GW10. For HW8, His1 occupies pocket B to serve as the N-terminal anchor residue. For GW10, the two small amino acids Gly 1 and Ser 2 at the N terminus occupy pocket A, which results in P3 serving as an anchor residue. In accordance with previous studies, the primary anchor specificity at the C terminus was found to be associated with aromatic residues (W and F), which is similar to the situation for HLA-B*57-restricted peptides. Conversely, the N-terminal anchor residues for Mamu-B*17 appear to have a broad chemical specificity (R, H, T, Q) due to the adjustment of pocket B (discussed below). In addition, the secondary anchor residues (P c-2 or P c-3 ) also display diverse conformations (Fig. 3A) . Residues highlighted in red are completely conserved, and residues in blue boxes are highly conserved (.80%). Green numbers denote residues that form disulfide bonds. Residues that play a critical role in the primary anchor pockets are highlighted with asterisks (residues in pocket B labeled in green, and residues in pocket F labeled in blue). Residues that are important for TCR recognition are highlighted with yellow boxes. The sequence alignment was generated using Clustal X (73) and ESPript (74).
Two comparisons are noteworthy (58, 59) . First, compared with HW8, GW10 has two more N-terminal residues (Gly 1 and Ser 2 ). However, the conformations of the central regions of the two peptides are essentially identical. Moreover, the solvent-accessible surface area for the central regions of HW8 (P3-P7) and GW10 (P5-P9) is similar (HW8 230 Å 2 , GW10 261.1 Å 2 ) (Fig. 3B) . In contrast, IW9 and IW11 present distinct conformations in the central region, although they share the first nine amino acids from their N termini. Specifically, IW11 contains two extra amino acids at the C terminus (Leu 10 and Trp 11 ), which induce a switch in the usage of the Pc anchor residue from Trp 9 in IW9 to Trp 11 in IW11 (Fig. 3C ). This Pc anchor switch causes the central region (P4-P10) of IW11 to protrude out of the groove and into the solvent, with the main chain of IW11 shifting up to 7.6 Å higher than the equivalent regions of IW9. Furthermore, the solvent-accessible surface area of the central region of IW9 (P4-P8, 161.1Å 2 ) shows ), which suggests that they might elicit qualitatively different TCR repertoires. Strikingly, a similar result has been reported for HLA-B*5703 (60) . Thus, our structures show two distinct strategies used by MHC Ι molecules to present N-or C-terminal truncated peptides, which may partially reflect the intrinsic characteristics of the peptides themselves. An alternative molecular model of GW10 in complex with Mamu-B*17 was produced using COOT and CCP4, in which the peptide uses Ser 2 as the P2 anchor, and Gly 1 hides in pocket A instead of protruding out of the peptide binding groove (Fig. 4) . Compared to the real Mamu-B*17-GW10 structure, however, we found that the interaction (van der Waal force and hydrogen bonds) between Ser 2 and pocket B in the alternative model was much weaker than the interaction between His 3 and pocket B in the real Mamu-B*17-GW10 structure. Thus, GW10 adopts a proper conformation with the lowest Gibb's free energy, which is similar to the situation for HW8.
Two types of binding mode in pocket D and different nonameric peptide conformations
The four nonameric peptides (IW9, FW9, QW9, and MW9) and one decameric peptide (GW10), which protrudes the additional P1 residue out of the groove, were compared in further analyses. As noted above, the second amino acid of GW10 is the small residue Ser, which is buried in pocket A. Thus, in this case, P3-P10 of GW10 is equivalent to P2-P9 of the nonameric peptides. Analysis of these five structures revealed that the conformation of nonamers presented by Mamu-B*17 can be divided into two types according to the binding mode in pocket D (Fig. 5) . Type I is common in mammalian MHC I molecules. In this mode, the P3 residue (referring to P2 as the anchor residue) occupies the D pocket, stacking against the side chain of Tyra 159 . Both Mamu-B*17-IW9 and Mamu-B*17-FW9, which contain bulky aromatic residues at P3 (Tyr 3 in IW9 and Trp 3 in FW9) that fit pocket D well, display this conformation. In type II, the P3 residues are relatively small, which contributes to the spaciousness of pocket D and allows the accommodation of side chains contributed by other peptide residues. Mamu-B*17-QW9, Mamu-B*17-MW9, and Mamu-B*17-GW10 all fall into this category. Previous studies have reported that water molecules (60-62), platform adjustment (60) , or the presence of only one flexible pocket contribute to the accommodation variability of bound peptides. However, none of these binding modes involve flexibility of the whole groove. Further analysis of the Mamu-B*17 structures indicated that the side chains of residues on both the a1/a2 helices and the b-sheet can adopt different conformations, which confer important flexibility to the peptide-binding groove for the accommodation of different peptide conformations (Fig. 6A) . Glua 45 , Arga 66 , Glua 69 , and Hisa 74 located on the a1 helix are all involved in interactions with bound peptides. Furthermore, the side chains of these four residues present various conformations to accommodate different peptides. For example, in the Mamu-B*17-IW9 and Mamu-B*17-GW10 structures, the side chains of Glua 69 extend in distinct directions as a consequence of the different P6 residues (corresponding to P7 in GW10) in these two peptides. Specifically, for IW9, the side chain of Thr 6 hydrogen bonds to the OE1 atom of Glua 69 , which forces the side chain of Glua 69 to orientate toward the peptide. In contrast, for GW10, the side chain of Gln 7 shifts 2.37 Å to form hydrogen bonds with the OE1/OE2 atoms of Glua 69 , causing the side chain of Glua 69 to protrude up out of the groove (Fig. 6B) .
In contrast to the central location of flexible residues in the a1 helix, the flexible residues in the a2 helix that are involved in peptide binding are distributed from the N terminus to the C terminus. Superposing whole residues comprising the peptide binding groove in the Mamu-B*17-IW9 and Mamu-B*17-IW11 structures revealed that Tyra 152 in the a2-helix of the H chain also contributes to different peptide accommodation modes (Fig. 6D) . Indeed, the side chain extends in totally different directions as a result of interactions with different peptide residues. Specifically, in case of the IW11 peptide, the side chain of Trp 9 is orientated toward the bottom of the peptide-binding groove, which forms a hydrogen bond to Lysa 97 . The side chain of Tyra 152 pokes toward the N terminus of the peptide, and the hydroxyl group hydrogen bonds to the side chains of Lysa 97 and Hisa 114 , respectively. In contrast, the side chain of Phe 7 in IW9 is directed toward the a2-helix and occupies pocket E, which forces the phenolic group of Tyra 152 to swivel away and leave enough space to accommodate the aromatic side chain. In the structures of Mamu-B*17 complexed with different peptides, H chain position 97 is located at the bottom of the peptide-binding groove as for other classical MHC I molecules. The conformational plasticity of Lysa 97 contributes to the accommodation of different peptide residues that insert into the central region of the groove accordingly. For example, in the Mamu-B*17-FW9 structure, the Lysa 97 side chain helps to stabilize the side chain of Glu 7 by forming a salt bridge. In the Mamu-B*17-MF8 structure, however, the side chain of Lysa 97 shifts 3.25Å to leave enough space for the hydrophobic side chain of Leu 5 (Fig.  6E) .
Unique primary anchor residues in pockets B and F of Mamu-B*17
In most mammalian MHC I molecules, the peptide-binding motif generally specifies two or more positions (anchor positions) at which all suitable peptides have either one or a very limited set of permissible residues (63, 64) . Strikingly, pocket B of Mamu-B*17 can bind a wide range of anchor residues. In accordance with previous data (36), the small residue T, the bulky residues R and H, and the bulky polar aliphatic residue Q, can all be accommodated in pocket B. On one hand, pocket B of Mamu-B*17 is much deeper compared with that of Mamu-A*01 and Mamu-A*02 (Fig.  7A) . Sequence analysis reveals that position 63 and position 67 in Mamu-A*01 and Mamu-A*02 are glutamine and methionine, respectively (Fig. 2) , the side chains of which are much longer than their counterparts in Mamu-B*17, thereby resulting in a relatively shallow pocket B. In contrast, the small alanine side chains in both positions 63 and 67 contribute to the spaciousness of pocket B in Mamu-B*17, enabling the accommodation of bulky anchor residues (Fig. 7A) . On the other hand, the unique charged Glua 45 , which is located at the bottom of pocket B, also plays an . This enables Mamu-B*17 pocket F to accommodate aromatic anchor residues. B, Binding strategies in pocket B. Four different anchor residues have the ability to bind pocket B; these are shown in pale cyan stick and sphere representations with hydrogen bonds and salt bridges indicated by dotted lines. For IW9 (magenta), the side chain of Arg 2 is stabilized by forming hydrogen bonds and salt bridges with Tyra 9 , Sera 24 , and Glua
45
, respectively. For QW9 (orange), the side chain of Thr 2 is too short to insert into the bottom of pocket B, which needs a water molecule to mediate the interactions among Thr 2 , Glua 45 , and Alaa
63
. For FW9 (salmon) and GW10 (cyan), the side chains of Gln 2 and His 3 hydrogen bond to Trya 9 and Glua 45 .
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on December 12, 2011 www.jimmunol.org shape of pocket F; these residues are conserved in HLA-B*5701. Although tyrosine occupies position 116 in HLA-B*5703 (Fig. 2) , the side chain is orientated toward the central region of the groove, allowing similar F-anchor preference.
Flexible TCR contact region
Previous studies have indicated that key residues on the a1 and a2 helices, including residues 65-76 and residues 149-156, play an important role in mediating pMHC I interactions with the TCR (65) (66) (67) . Notably, these residues in Mamu-B*17 present highly flexible conformations, which may influence TCR repertoire profiles (Fig. 8) . Position 69 and position 155 have been reported as crucial residues for TCR interactions (67) . Sequence analysis reveals that Glua 69 and Arga 155 in Mamu-B*17 are unique (Fig.  2) , as the corresponding residues in other primate MHC I molecules are noncharged (S and Q). These unique features may contribute to a more flexible juxtaposition at the TCR-pMHC I interface, with potential implications for TCR repertoire engagement.
Discussion
The Mamu-B*17 allele is prevalent among rhesus macaques and consistently associated with efficacious control of SIV replication. In this article, we describe the structures of eight different immunodominant SIV mac 239-derived CTL-epitope peptides complexed with Mamu-B*17, thereby providing the first insights into the atomic basis of Ag presentation by this protective MHC I molecule.
The peptide-binding specificity of Mamu-B*17 has been characterized previously in functional studies (36) . Pocket B and pocket F are clearly the dominant peptide anchor sites, as observed for other MHC I complexes. N-terminal peptide anchor residues display a broad chemical specificity, encompassing basic residues (H and R), a bulky polar aliphatic residue (Q), and a small residue (T). This diverse profile is determined by two main structural features of the Mamu-B*17 molecule. First, pocket B of Mamu-B*17 is much deeper and larger than that of either Mamu-A*01 or Mamu-A*02 (50, 68) , which provides more space for bulky residues. In contrast, pocket B of Mamu-A*01 can only accommodate small residues (S and T) (50) . Second, the conformational adjustment of side chains and water molecule compensation confer substantial plasticity within pocket B. Single substitution analog assays have shown that negatively charged residues (D and E) are not tolerated at position 2 (36), which may be partially explained by the Glua 45 residue positioned at the bottom of pocket B. Pocket F in the Mamu-B*17 molecule is particularly distinctive in that it confers a preference for bulky aromatic residues, especially tryptophan, as the C terminus of the bound peptide. Many HLA-B*57 suballeles show similar Cterminal anchor residue preference due to the presence of identical key residues in this pocket (60) . Previous studies have failed to detect the emergence of natural mutations that change the C terminus tryptophan anchor residue (69) . Given that tryptophan is a rare amino acid, encoded only by one codon, these observations indicate that such variation would likely impact viral fitness and provide a rationale for the protective effect of Mamu-B*17-restricted epitope presentation.
The conformations of the eight peptide epitopes complexed to Mamu-B*17 described in this study are distinct, which suggests the potential to elicit a broad range of protective CD8 + T cell responses. In addition, many studies show that water molecules, platform adjustment, or the presence of only one flexible pocket contribute to the accommodation of different peptides (60) (61) (62) . In contrast, Mamu-B*17 has a whole flexible peptide-binding groove to achieve this. Furthermore, Mamu-B*17 appears to maintain the ability to bind variant epitopes, which may elicit cross-reactive TCRs or specific de novo responses (43) . It is tempting to speculate that the unique flexibility within the Mamu-B*17 binding groove may enable the accommodation of natural epitope variants, thereby providing a novel explanation for the containment of viral replication by this MHC I molecule.
TCR cross-reactivity (18, 70) or variant-specific de novo responses (71, 72) might be important for the maintenance of SIV control in ECs. Among the structures determined in this study, two sets of related peptides present distinct outcomes. The GW10 and HW8 peptides display identical main-chain and side-chain conformations, although GW10 contains two more amino acids (Gly 1 and Ser 2 ) at the N terminus. Thus, HW8 and GW10 might elicit similar TCR repertoires. In contrast, IW9 and IW11 display distinct main-chain conformations across the central region. Specifically, IW11 extends two more amino acids (Leu 10 and Trp 11 ) at the C terminus, inducing an anchor residue shift in pocket F. Consequently, the central region of IW11 bulges out of the groove, which likely plays a dominant role in TCR recognition. The identical main-chain conformations of the P1 to P4 and the Pc-1 to Pc-2 residues in IW9 and IW11 lock both the N terminus and C terminus, respectively. Two related epitopes, KF8 and KF11, show similarly distinct features when bound to HLA-B*5703 (60) . The structures of Mamu-B*17 complexed with different peptides therefore provide insights into the relationship between different epitopes. However, extrapolations to TCR repertoire engagement remain untested and require further exploration.
In summary, the current study provides novel insights into the structural basis of diverse peptide accommodation by Mamu-B*17 and highlights unique atomic features that might contribute to the protective effect of this MHC I molecule in SIV infection.
